(Q36262437)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

HIV entry inhibitors: a new generation of antiretroviral drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

main subject

anti-retroviral agent

0 references

author

Dimitrios Spandidos

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Elias Krambovitis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Filippos Porichis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

Acta Pharmacologica Sinica

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

1165-1173

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

Global impact of human immunodeficiency virus and AIDS.

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

21 January 2018

Mucosal HIV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Activation-induced CD4+ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4+ T cell count, and HIV plasma viral copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Simple electrostatic interaction mechanisms in the service of HIV-1 pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Anti-HIV drug development--an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Microbicides: a new approach to preventing HIV and other sexually transmitted infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Inhibiting sexual transmission of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

CXCR4-dependent infection of CD8+, but not CD4+, lymphocytes by a primary human immunodeficiency virus type 1 isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Dys-regulation of effector CD4+ T cell function by the V3 domain of the HIV-1 gp120 during antigen presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Atomic structure of the ectodomain from HIV-1 gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

HIV infection--a new drug and new costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Fusion inhibition--a major but costly step forward in the treatment of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Conformational properties of HIV-1 gp120/V3 immunogenic domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Protein design of an HIV-1 entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00193.X

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

21 January 2018

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.6189183

Identifiers

DOI

10.1111/J.1745-7254.2005.00193.X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16174430%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 January 2020

1046337497

0 references

1 reference